レーバー先天性黒内障の世界市場

レーバー先天性黒内障の世界市場は2030年までに15億米ドルに達する

2024年に12億米ドルと推定されるレーバー先天性黒内障の世界市場は、分析期間2024-2030年にCAGR 3.9%で成長し、2030年には15億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである遺伝子治療は、CAGR4.7%を記録し、分析期間終了時には6億2,050万米ドルに達すると予想されます。医薬品セグメントの成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は3億2,570万米ドルと推定、中国はCAGR7.3％で成長予測

米国のレーバー先天性黒内障市場は、2024年に3億2,570万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億590万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と3.0％と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界のレーバー先天性黒内障市場- 主要動向と促進要因まとめ

遺伝子の発見が診断と介入経路をどう変えるか？

早期の小児失明を引き起こすまれな遺伝性網膜疾患であるレーバー先天性黒内障（LCA）の理解は、分子遺伝学とゲノム医学の飛躍的進歩により、過去10年間で急速に進みました。歴史的には、LCAは出生時または乳児期早期の重度の視力障害などの臨床症状と網膜電図（ERG）の特徴的な異常に基づいて診断されていました。しかし、RPE65、CEP290、CRB1、GUCY2Dなど、LCAに関連する25以上の異なる遺伝子変異が発見されたことにより、次世代シーケンサー（NGS）や全エクソーム解析を用いた精密診断へのシフトが可能になりました。遺伝子検査は今や主要な診断手段であり、基礎となる変異の確実な同定を提供し、臨床医が表現型的に類似した網膜疾患を鑑別することを可能にしています。

このようにゲノムが明らかになったことで、変異に特異的な治療法、特に遺伝子置換や遺伝子編集戦略の道が開かれつつあります。例えば、RPE65を介するLCAに対するvoretigene neparvovec（Luxturnaとして販売）のFDA承認は、LCAコミュニティのみならず、眼遺伝子治療分野全体にとって大きなマイルストーンとなります。このような開発は、特に有病率の高い地域や近親婚の集団において、早期スクリーニングや家族遺伝カウンセリングを奨励しています。このような取り組みは、遺伝的、表現型的、縦断的データを集約するバイオバンク構想や共同臨床登録によってさらに支援され、臨床試験と商業的経路開発の両方を加速させています。

治療を再定義する上で、再生治療と標的治療はどのような役割を果たすのか？

LCAの臨床管理は、支持的な視覚リハビリテーションから、疾患の根本原因を標的とした介入へと発展してきました。遺伝子治療は、特に網膜への導入に最適化されたアデノ随伴ウイルス（AAV）ベクターの出現により、注目され続けています。これらの治療法は、欠陥遺伝子の機能的コピーを視細胞や網膜色素上皮（RPE）細胞に直接導入し、分子レベルで視覚サイクルを回復させることを目的としています。現在承認されている遺伝子治療はLuxturnaのみであるが、他のLCA関連遺伝子をターゲットとする多数のパイプライン候補が臨床および前臨床試験中です。CRISPRに基づく遺伝子編集、特にCEP290変異に対する研究も盛んになってきており、繰り返し投与することなく持続的な矯正が期待できます。

同時に、視細胞がすでに失われている進行性網膜変性患者の視力を回復させるために、網膜細胞移植や光遺伝学などの再生アプローチが検討されています。遺伝子導入により残存する網膜細胞を光感受性にするオプトジェネティクスは、特に後期LCAに有望です。これらの進歩は、スクリーニングによって早期に発見された変異保有者の変性を遅らせることを目的とした神経保護剤や抗酸化療法の治験的使用によって補完されます。装着型ロービジョン装置や感覚代替システムなどの支援技術は、特に侵襲的治療が不適格な患者に対して、補足的な支援を提供し続けています。

臨床試験、希少疾病用医薬品のインセンティブ、支援ネットワークは市場力学にどのような影響を与えているか？

市場情勢は、希少疾病に分類され、複数の法域で希少疾病用医薬品の優遇措置、ファストトラック指定、画期的治療薬に認定されていることに大きく影響されています。これらの規制メカニズムは、LCAをターゲットとした治療を市場に投入するのに必要な時間とコストを大幅に削減しています。LCA遺伝子治療の臨床試験は、北米、欧州、アジアにおいて、官民パートナーシップに支えられた専門センターで実施されることが多くなっています。これらの臨床試験は、実世界の集団における長期的な有効性と安全性を記録する必要性を反映し、適応プロトコール、患者報告アウトカム、市販後のデータ収集を中心にデザインされることが多くなっています。

患者支援団体は、患者のリクルートと認知度向上に貢献するだけでなく、初期段階の研究に資金を提供し、公平な償還モデルを求めてロビー活動を行うなど、この分野における重要なイネーブラーとして台頭してきました。彼らの関与により、治療法の開発において患者中心の設計が確実に統合されるようになり、解剖学的なエンドポイントだけでなく、QOL、光感受性、機能的視力の改善が重視されるようになりました。これと並行して、診断インフラも世界的に改善されつつあり、新生児スクリーニングプログラムや小児視力健康キャンペーンでは、罹患率の高い地域でLCAの遺伝子検査が取り入れられています。このような統合された枠組みは、臨床試験へのアクセスを加速し、新興市場全体の患者特定パイプラインを強化しています。

レーバー先天性黒内障治療市場の成長の原動力は何か？

レーバー先天性黒内障治療市場の成長は、科学的イノベーション、政策支援、希少疾患治療に対する市場の準備態勢に根ざしたいくつかの要因によって牽引されています。遺伝学的検査の入手可能性と価格の向上は、治療適格性と市場参入の前提条件である診断対象患者を大幅に拡大しています。より多くの変異が同定され、明確な疾患表現型と関連付けられるにつれて、特定の遺伝子型を標的とした層別化治療の可能性が広がっています。また、このような遺伝子の細分化により、より焦点を絞った臨床開発が可能になり、従来リスクの高かった治療領域への投資のリスクを軽減することができます。

製薬会社やバイオテクノロジー企業は、LCAを、網膜色素変性症やスターガルト病などの他の遺伝性網膜疾患に拡張可能な眼遺伝子治療プラットフォームのゲートウェイ適応症と見なすようになってきています。このようなプラットフォームの可能性は、ベンチャーキャピタルからの投資、ライセンス契約、買収活動を活発化させ、市場に財務的・技術的な勢いをもたらしています。一方、米国、EU、アジアの一部の市場における償還環境は、バリューベースや年金支払いモデルを通じて1回限りの遺伝子治療をサポートするように進化しており、商業的実行可能性を高めています。

さらに、認知度向上キャンペーン、臨床医教育、遺伝カウンセリングの日常的な眼科ワークフローへの統合により、より早期の紹介と介入が促進されつつあります。世界の共同研究コンソーシアムの台頭と実世界のエビデンスフレームワークは、スケーラブルな治療提供の基盤をさらに強固なものにしています。これらの力を総合すると、LCA治療市場はニッチな分野から、科学的に検証され、商業的に支援される、世界の関連性が高まる治療フロンティアへと変貌しつつあります。

セグメント

治療タイプ（遺伝子治療、医薬品、網膜補綴、補助器具、その他の治療タイプ）、標的遺伝子（RPE65、GUCY2D、AIPL1、RPGRIP1、CEP290、その他の遺伝子）、エンドユーザー（病院、眼科専門クリニック、眼科研究センター、在宅医療現場、その他のエンドユーザー）

調査対象企業の例（注目の48社）

• AbbVie Inc.
• Allergan, Inc.
• Apellis Pharmaceuticals
• Astellas Pharma Inc.
• Atsena Therapeutics
• Avexis（a Novartis company）
• Biogen Inc.
• Editas Medicine
• Eyenovia, Inc.
• GenSight Biologics
• Gilead Sciences, Inc.
• Horizon Therapeutics plc
• HuidaGene Therapeutics
• Novartis AG
• Ocugen, Inc.
• Opus Genetics
• Orphan Biovitrum AB（Sobi）
• ProQR Therapeutics
• Regeneron Pharmaceuticals, Inc.
• Spark Therapeutics

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Leber Congenital Amaurosis Market to Reach US$1.5 Billion by 2030

The global market for Leber Congenital Amaurosis estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Gene Therapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$620.5 Million by the end of the analysis period. Growth in the Pharmaceutical Drugs segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$325.7 Million While China is Forecast to Grow at 7.3% CAGR

The Leber Congenital Amaurosis market in the U.S. is estimated at US$325.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$305.9 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Leber Congenital Amaurosis Market - Key Trends & Drivers Summarized

How Are Genetic Discoveries Transforming Diagnosis and Intervention Pathways?

The understanding of Leber Congenital Amaurosis (LCA), a rare inherited retinal disorder causing early childhood blindness, has advanced rapidly over the last decade due to breakthroughs in molecular genetics and genomic medicine. Historically, LCA was diagnosed based on clinical symptoms such as severe visual impairment at birth or in early infancy, along with characteristic abnormalities in electroretinogram (ERG) results. However, the discovery of over 25 distinct gene mutations associated with LCA-including RPE65, CEP290, CRB1, and GUCY2D-has enabled a shift toward precision diagnostics using next-generation sequencing (NGS) and whole exome analysis. Genetic testing is now a primary diagnostic modality, providing definitive identification of the underlying mutation and enabling clinicians to differentiate between phenotypically similar retinal disorders.

This genomic clarity is opening up avenues for mutation-specific therapies, particularly gene replacement and gene editing strategies. For example, the FDA approval of voretigene neparvovec (marketed as Luxturna) for RPE65-mediated LCA represents a major milestone, not only for the LCA community but for the field of ocular gene therapy as a whole. Such developments are encouraging earlier screening and family genetic counseling, especially in high-prevalence regions and populations with consanguineous marriages. These initiatives are further supported by biobank initiatives and collaborative clinical registries that aggregate genetic, phenotypic, and longitudinal data, accelerating both clinical trials and commercial pathway development.

What Role Does Regenerative and Targeted Therapy Play in Redefining Treatment?

The clinical management of LCA has evolved from supportive visual rehabilitation toward interventions targeting the root cause of the disease. Gene therapy continues to gain prominence, particularly with the emergence of adeno-associated virus (AAV) vectors optimized for retinal delivery. These therapies aim to deliver functional copies of defective genes directly into photoreceptor or retinal pigment epithelial (RPE) cells, restoring the visual cycle at the molecular level. While Luxturna remains the only approved gene therapy to date, numerous pipeline candidates targeting other LCA-related genes are under clinical and preclinical investigation. Research into CRISPR-based gene editing, especially for CEP290 mutations, is also gaining traction, offering promise for durable correction without the need for repeated dosing.

Simultaneously, regenerative approaches such as retinal cell transplantation and optogenetics are being explored to restore vision in patients with advanced retinal degeneration where photoreceptor cells are already lost. Optogenetics, which involves making remaining retinal cells photosensitive through gene transfer, is particularly promising for late-stage LCA. These advancements are complemented by investigational use of neuroprotective agents and antioxidant therapies aimed at slowing degeneration in mutation carriers identified early through screening. Assistive technologies such as wearable low-vision devices and sensory substitution systems continue to offer supplementary support, particularly for patients ineligible for invasive therapies.

How Are Clinical Trials, Orphan Drug Incentives, and Advocacy Networks Influencing Market Dynamics?

The market landscape for LCA is heavily influenced by its classification as a rare disease, which qualifies it for orphan drug incentives, fast-track designations, and breakthrough therapy status in multiple jurisdictions. These regulatory mechanisms have significantly reduced the time and cost required to bring LCA-targeted treatments to market. Clinical trials for LCA gene therapies are being conducted at a growing number of specialized centers of excellence in North America, Europe, and Asia, often backed by public-private partnerships. These trials are increasingly designed around adaptive protocols, patient-reported outcomes, and post-marketing data capture, reflecting the need to document long-term efficacy and safety in real-world populations.

Patient advocacy groups have emerged as critical enablers in this space, contributing not only to patient recruitment and awareness but also funding early-stage research and lobbying for equitable reimbursement models. Their involvement has helped ensure the integration of patient-centric design in therapy development, emphasizing improvements in quality of life, light sensitivity, and functional vision rather than solely anatomical endpoints. In parallel, diagnostic infrastructure is improving globally, with newborn screening programs and pediatric vision health campaigns incorporating genetic testing for LCA in regions with high incidence rates. These integrated frameworks are accelerating access to clinical trials and bolstering patient identification pipelines across emerging markets.

What Is Fueling Growth Momentum in the Leber Congenital Amaurosis Treatment Market?

The growth in the Leber Congenital Amaurosis treatment market is driven by several factors rooted in scientific innovation, policy support, and market readiness for rare disease therapies. The increasing availability and affordability of genetic testing are significantly expanding the pool of diagnosed patients, a prerequisite for both treatment eligibility and market uptake. As more mutations are identified and linked to distinct disease phenotypes, the potential for stratified therapies targeting specific genotypes is widening. This genetic granularity also allows for more focused clinical development, de-risking investment in a traditionally high-risk therapeutic area.

Pharmaceutical and biotech companies are increasingly viewing LCA as a gateway indication for ocular gene therapy platforms that can be extended to other inherited retinal diseases such as retinitis pigmentosa and Stargardt disease. This platform potential has catalyzed venture capital investments, licensing agreements, and acquisition activity, infusing the market with both financial and technological momentum. Meanwhile, reimbursement environments in the U.S., EU, and select Asian markets are evolving to support one-time gene therapies through value-based and annuity payment models, enhancing commercial viability.

Additionally, awareness campaigns, clinician education, and integration of genetic counseling into routine ophthalmology workflows are fostering earlier referrals and intervention. The rise of global collaborative research consortia and real-world evidence frameworks further strengthens the foundation for scalable treatment delivery. Taken together, these forces are transforming the LCA treatment market from a niche field to a scientifically validated, commercially supported therapeutic frontier with growing global relevance.

SCOPE OF STUDY:

The report analyzes the Leber Congenital Amaurosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Other Treatment Types); Target Gene (RPE65, GUCY2D, AIPL1, RPGRIP1, CEP290, Other Genes); End-User (Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• AbbVie Inc.
• Allergan, Inc.
• Apellis Pharmaceuticals
• Astellas Pharma Inc.
• Atsena Therapeutics
• Avexis (a Novartis company)
• Biogen Inc.
• Editas Medicine
• Eyenovia, Inc.
• GenSight Biologics
• Gilead Sciences, Inc.
• Horizon Therapeutics plc
• HuidaGene Therapeutics
• Novartis AG
• Ocugen, Inc.
• Opus Genetics
• Orphan Biovitrum AB (Sobi)
• ProQR Therapeutics
• Regeneron Pharmaceuticals, Inc.
• Spark Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Leber Congenital Amaurosis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Gene Therapy Platforms Propel Innovation in LCA Treatment Modalities
  • Increased Genetic Screening Capabilities Throw the Spotlight on Early Disease Detection
  • Growing Pipeline of Retinal Therapies Expands Addressable Market for Rare Ophthalmic Disorders
  • Regulatory Approvals of Targeted Therapies Strengthen Business Case for Novel LCA Treatments
  • Expansion of Precision Medicine Approaches Drives Customization of Genetic Therapies
  • Supportive Orphan Drug Incentives Sustain Research Investments in Inherited Retinal Disorders
  • Increasing Use of CRISPR and Genome Editing Technologies Accelerates Therapeutic Development
  • Collaborations Between Biotech Firms and Research Institutes Generate Innovation Pipelines
  • Technological Advancements in Retinal Imaging Facilitate Accurate Disease Monitoring
  • Patient Advocacy and Awareness Campaigns Propel Enrollment in Clinical Trials
  • Investments in mRNA and Viral Vector Platforms Open New Opportunities for Gene Delivery
  • Cross-Border Research Collaborations Strengthen Global Clinical Development Programs
  • Development of Regenerative Ophthalmology Tools Sustains Hope for Vision Restoration
  • Expanded Funding for Rare Disease Research Drives Innovation in Early-Stage Candidates
  • Focus on Minimizing Disease Progression Strengthens Support for Early Interventions
  • Challenges in Long-Term Therapy Efficacy Highlight Unmet Needs in Post-Treatment Monitoring
  • Rising Interest in Ocular Drug Delivery Systems Enhances Bioavailability of Therapies
  • Shift Toward In-Clinic Genetic Counseling Services Expands Patient Engagement Models
  • Regulatory Harmonization Across Regions Facilitates Global Therapy Accessibility
  • Digital Health Tools for Vision Monitoring Drive Patient-Centered Care in Rare Eye Diseases
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Leber Congenital Amaurosis Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Leber Congenital Amaurosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Leber Congenital Amaurosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Retinal Prosthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Retinal Prosthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Retinal Prosthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Assistive Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Assistive Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Assistive Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for CEP290 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for CEP290 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for CEP290 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Genes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Genes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Genes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for RPE65 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for RPE65 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for RPE65 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for GUCY2D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for GUCY2D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for GUCY2D by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for AIPL1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for AIPL1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for AIPL1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for RPGRIP1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for RPGRIP1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for RPGRIP1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Specialized Eye Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Specialized Eye Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Specialized Eye Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Ophthalmology Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Ophthalmology Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Ophthalmology Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Home Care Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Home Care Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• JAPAN
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• CHINA
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• EUROPE
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Leber Congenital Amaurosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Leber Congenital Amaurosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• FRANCE
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• GERMANY
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 128: UK Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Leber Congenital Amaurosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Leber Congenital Amaurosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Australia 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• INDIA
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 185: India Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 191: India Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: India 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: South Korea 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Leber Congenital Amaurosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Leber Congenital Amaurosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Latin America 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Argentina 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Brazil 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Mexico 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Leber Congenital Amaurosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Leber Congenital Amaurosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Middle East 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Iran 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Israel 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: UAE 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030
• AFRICA
  • Leber Congenital Amaurosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Leber Congenital Amaurosis by Treatment Type - Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Leber Congenital Amaurosis by Treatment Type - Percentage Breakdown of Value Sales for Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Leber Congenital Amaurosis by Target Gene - CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Leber Congenital Amaurosis by Target Gene - Percentage Breakdown of Value Sales for CEP290, Other Genes, RPE65, GUCY2D, AIPL1 and RPGRIP1 for the Years 2015, 2025 & 2030
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Leber Congenital Amaurosis by End-user - Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Africa 15-Year Perspective for Leber Congenital Amaurosis by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION